|
| Home : Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma |
|
Dec 22
2020 |
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma |
|
THOUSAND OAKS, Calif., Dec. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/update-on-source-phase-3-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma-301197136.html |
| |
|
Related News
|
» Skanska divests majority interest in 2+U in Seattle, USA, for USD 669M, about SEK 5.5 billion
» In a year like no other, TENCEL(TM) perseveres with incredible accomplishments to drive greater sustainability ecosystem
|
|
|
